Veracyte, Inc. (VCYT)
After hours:
| Previous close | 22.60 |
| Open | 22.83 |
| Bid | 21.95 x 800 |
| Ask | 23.67 x 800 |
| Day's range | 22.20 - 22.89 |
| 52-week range | 14.92 - 32.40 |
| Volume | |
| Avg. volume | 576,137 |
| Market cap | 1.635B |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
SOUTH SAN FRANCISCO, Calif., September 21, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in Washington, DC from September 27 to October 1. Together, these abstracts offer novel insights into the molecular underpinnings of thyroid nodules and tumors based on whole-transcriptome RNA sequencing data from
- Business Wire
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
SOUTH SAN FRANCISCO, Calif., September 07, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France. She will lead the global expansion of Veracyte’s tests and will also serve as site lead for the company’s Marseille operations. Dr. Taine is a highly credentialed commercial operations leader with 30 years of experience in the medical device and pharmace
- Business Wire
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
SOUTH SAN FRANCISCO, Calif. & PARIS, September 06, 2023--Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies. The multi-year partnership will leverage Gustave Rou
